CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES
CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES IRVINE, Calif., Dec. 20 /PRNewswire/ -- Cytocare Inc.
(NASDAQ: CYTI) announced the acquisition of world-wide exclusive rights for diagnostic, prognostic and therapeutic uses of certain hybridoma cell lines and their prostate monoclonal antibodies. The patented molecules were licensed from the Sloan-Kettering Institute for Cancer Research.
These compounds, after further rigorous testing, might be developed for potential use as biopharmaceutical agents for prostate disease. Cytocare is developing a family of molecules for the diagnosis and treatment of benign prostatic hypertrophy and prostate cancer. Pharmaceutical projects inherently are high risk. In 1992, Cytocare intends to expand research and development in small molecule synthesis, human monoclonal antibodies and conjugation chemistry for prostate disease. Urology Marketing Efforts Expands Cytocare also announced that Medstone International Inc., its manufacturing subsidiary, added two new distributors for both U.S. and foreign markets: the Liebel-Flarsheim Co., a leading supplier of urological examining rooms, and Lithotech Inc., a supplier of lithotripsy hardware. -0- 12/20/91 /CONTACT: Jeannine Cormane of Cytocare Inc., 714-587-0500, ext. 345/ (CYTI) CO: Cytocare Inc. ST: California IN: MTC SU:
DM-CH -- LA010 -- 4394 12/20/91 12:55 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 20, 1991|
|Previous Article:||GLOBAL OCEAN CARRIERS ANNOUNCES COMPLETION OF RIGHTS OFFERING SALE OF 1,111,111 SHARES RAISED GROSS PROCEEDS OF $5,000,000|
|Next Article:||1992 PORSCHE 968 LAUNCHED AT $39,850 SUGGESTED RETAIL PRICE|